KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops and markets small molecule protease inhibitors for diseases with unmet need. The company’s product portfolio includes small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that has completed a phase II clinical trial for the treatment of DME; KVD900, which is in a phase II clinical trial to treat HAE attacks; and KVD824, an oral plasma kallikrein inhibitor that has completed a phase I clinical trial for the treatment of AMD or HAE. The company is headquartered in Cambridge, Massachusetts.
Looking for how to buy shares of KalVista Pharmaceuticals (KALV), Step by step in Spanish
Are you interested in buying KalVista Pharmaceuticals (KALV) shares on Nasdaq risk-free and using a regulated broker? Would you like to be able to invest your profits from the piggy bank and extract capital gains on the stock market? In this tutorial I am going to show you how you can invest in Degiro , a reliable German investment broker with very low commissions, and how you can acquire shares in KalVista Pharmaceuticals, Inc. (KALV) (KALV) quickly and easily. simple.
The method to follow is intuitive :
- To begin we will register in DeGiro, an interface in which we will buy shares of KalVista Pharmaceuticals, Inc. (KALV) with the ticker (KALV).
- In the second step we will enter capital and then execute the 1st investment.
- Once we see the funds we will have to locate the company KalVista Pharmaceuticals by putting the TICKER, which is KALV, in the search engine.
- Then we will only have to add the number of shares we want, the price at which we buy and the type of order.
It is possible that this tutorial has been somewhat basic for you, so I am going to show you the process with images.
How to open your account in DeGiro
As a first step we will register in DeGiro from this link :
It will ask us for an email, a name and a pin code to enter, and later we must continue from the link that they have sent us by e-mail.
Then Degiro will ask us for some essential information in order to approve our official identification . We must have in hand the passport, ID or driving document, the mobile and the number of the bank account that we are going to use to make our first deposit. If you do not understand what this format is, you can review this simple usage tutorial that we have prepared .
Once our account is admitted we will be able to put money from the Deposit / Withdraw tab. We have the possibility of making a bank transaction that will take 1-3 days, or make the deposit instantly with Sofort, a 100% secure and very reliable payment gateway.
How to buy KalVista Pharmaceuticals (KALV) shares through DEGIRO
As soon as we have the capital we can invest in our first action. You can use the place order button that you will find in the upper right corner or use the DeGiro search engine and paste the ticker. In the following image you will find that I have put the Amazon ticker but you must put (KALV), the KalVista Pharmaceuticals ticker. As we are talking about an action, we will discover that the related businesses and companies are listed and there we will see KalVista Pharmaceuticals. The fundamental thing is that the ticker, the name of the company and the market in which it is listed coincide. Amazon is listed on Nasdaq (NDQ) and in your case KalVista Pharmaceuticals, Inc. (KALV) is listed on Nasdaq. This step is essential so make no mistake.
When placing the order, we must pay special attention to the following . We will have the possibility of placing a limit or market order. Imagine that you want to buy a share of KalVista Pharmaceuticals at 26.56, but its current price is much higher. With a limit order we are going to put the value at which we want to execute the operation and until there are no shares selling at this value, the acquisition of the share will not be carried out. With a market order, DeGiro will buy the number of shares that we have indicated at the current selling price, which will be closely related to the current trading price.
In any circumstance, it is convenient that you look at the type of classification: fixed or of the day . For example, in Spain, the stock market listing is in the morning until 1:00 p.m., and in the US it corresponds to the afternoon schedule in Spain. If the order is fixed, it will remain until the point where it can be executed, but if you prefer the “of the day” option, at the time the trading session ends, if it has not been executed, it will be removed from your history from Activity – Orders in process.
I would love that this simple post has helped you to invest in KalVista Pharmaceuticals. Until another!
| Company information |
|
company executives
| Name | Title | Payment | exercised | Year of birth |
|---|---|---|---|---|
| Mr Thomas Andrew Crockett | CEO and Director | 568k | N/A | 1975 |
| Mr. Benjamin L. Palleiko | Chief Bus Officer and CFO | 446.9 thousand | N/A | 1966 |
| Mr. Christopher M. Yea Ph.D. | Chief Develop. Official | 445.27k | N/A | 1964 |
| Dr. Edward P. Feener | Scientific Director | N/A | N/A | 1960 |
| Leah Monteiro | Director of Corporate Communications and Investor Relations | N/A | N/A | N/A |
| Mrs. Rachel Morten | Head of Regulatory Affairs and Quality Control | N/A | N/A | N/A |
| Mr Andreas Maetzel | Senior Vice President of Medicine | N/A | N/A | 1963 |
| Mr. Michael D. Smith Pharm.D. | Vice President Mr. de Devel. | N/A | N/A | 1979 |
| Mr Stephen Donnelly | Director of Finance and Company Sec. | N/A | N/A | N/A |
| Mr. John B. McKune | End VP. | N/A | N/A | 1976 |
Recent KalVista Pharmaceuticals Events:
Recent Events July 02, 2020 Filed Complete 8-K: Results of Operations and Financial Condition, Financial Statement July 01, 2020 Filed Complete 10-K: Annual Report June 11, 2020 Filed Complete 8-K: Amendments to Articles of Inc. or statutes; Change in Fiscal Year, March F10, 2020 Filed Complete 8-K: Results of Operations and Financial Condition, Financial Statement March 10, 2020 Filed Complete 10-Q: Quarterly Report